{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:21:04Z","timestamp":1777879264036,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T00:00:00Z","timestamp":1546560000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T00:00:00Z","timestamp":1546560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP16ck0106106"],"award-info":[{"award-number":["JP16ck0106106"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP16ck0106106"],"award-info":[{"award-number":["JP16ck0106106"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP16ck0106106"],"award-info":[{"award-number":["JP16ck0106106"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1038\/s41417-018-0075-5","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T11:24:03Z","timestamp":1546514643000},"page":"388-399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Overexpression of SOCS3 mediated by adenovirus vector in mouse and human castration-resistant prostate cancer cells increases the sensitivity to NK cells in vitro and in vivo"],"prefix":"10.1038","volume":"26","author":[{"given":"Tomomi","family":"Yoneda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Kunimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Narikiyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoki","family":"Ishiko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9682-2548","authenticated-orcid":false,"given":"Naoki","family":"Otsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Nibu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Serada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuji","family":"Naka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,4]]},"reference":[{"key":"75_CR1","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/cas.13194","volume":"108","author":"S Chikuma","year":"2017","unstructured":"Chikuma S, Kanamori M, Mise-Omata S, Yoshimura A. Suppressors of cytokine signaling: potential immune checkpoint molecules for cancer immunotherapy. Cancer Sci. 2017;108:574\u201380.","journal-title":"Cancer Sci"},{"key":"75_CR2","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/ijc.25716","volume":"129","author":"K Iwahori","year":"2011","unstructured":"Iwahori K, Serada S, Fujimoto M, Nomura S, Osaki T, Lee CM, et al. Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma. Int J Cancer. 2011;129:1005\u201317.","journal-title":"Int J Cancer"},{"key":"75_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrc1275","volume":"4","author":"H Yu","year":"2004","unstructured":"Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer. 2004;4:97\u2013105.","journal-title":"Nat Rev Cancer"},{"key":"75_CR4","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1002\/ijc.27318","volume":"130","author":"J Zhang","year":"2012","unstructured":"Zhang J, Li H, Yu JP, Wang SE, Ren XB. Role of SOCS1 in tumor progression and therapeutic application. Int J Cancer. 2012;130:1971\u201380.","journal-title":"Int J Cancer"},{"key":"75_CR5","doi-asserted-by":"publisher","first-page":"e0123133","DOI":"10.1371\/journal.pone.0123133","volume":"10","author":"MH Kim","year":"2015","unstructured":"Kim MH, Kim MS, Kim W, Kang MA, Cacalano NA, Kang SB, et al. Suppressor of cytokine signaling (SOCS) genes are silenced by DNA hypermethylation and histone deacetylation and regulate response to radiotherapy in cervical cancer cells. PLoS ONE. 2015;10:e0123133.","journal-title":"PLoS ONE"},{"key":"75_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3816\/CLC.2004.n.015","volume":"5","author":"B He","year":"2004","unstructured":"He B, You L, Xu Z, Mazieres J, Lee AY, Jablons DM. Activity of the suppressor of cytokine signaling-3 promoter in human non-small-cell lung cancer. Clin Lung Cancer. 2004;5:366\u201370.","journal-title":"Clin Lung Cancer"},{"key":"75_CR7","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1002\/ijc.30666","volume":"140","author":"T Sugase","year":"2017","unstructured":"Sugase T, Takahashi T, Serada S, Nakatsuka R, Fujimoto M, Ohkawara T, et al. Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice. Int J Cancer. 2017;140:2608\u201321.","journal-title":"Int J Cancer"},{"key":"75_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0366-5","volume":"14","author":"W Wen","year":"2015","unstructured":"Wen W, Wu J, Liu L, Tian Y, Buettner R, Hsieh MY, et al. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK\/STAT3 pathways in human ovarian cancer. Mol Cancer. 2015;14:100.","journal-title":"Mol Cancer"},{"key":"75_CR9","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359\u2013386.","journal-title":"Int J Cancer"},{"key":"75_CR10","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1038\/onc.2013.206","volume":"32","author":"T Karantanos","year":"2013","unstructured":"Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32:5501\u201311.","journal-title":"Oncogene"},{"key":"75_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G","volume":"42","author":"W Lou","year":"2000","unstructured":"Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate. 2000;42:239\u201342.","journal-title":"Prostate"},{"key":"75_CR12","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell . 2017;170:1109\u201319.","journal-title":"Cell"},{"key":"75_CR13","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","volume":"36","author":"J Chesney","year":"2018","unstructured":"Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2018;36:1658\u201367.","journal-title":"J Clin Oncol"},{"key":"75_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.canlet.2011.04.024","volume":"308","author":"K Hiwatashi","year":"2011","unstructured":"Hiwatashi K, Tamiya T, Hasegawa E, Fukaya T, Hashimoto M, Kakoi K, et al. Suppression of SOCS3 in macrophages prevents cancer metastasis by modifying macrophage phase and MCP2\/CCL8 induction. Cancer Lett. 2011;308:172\u201380.","journal-title":"Cancer Lett"},{"key":"75_CR15","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1111\/cas.13332","volume":"108","author":"H Kitamura","year":"2017","unstructured":"Kitamura H, Ohno Y, Toyoshima Y, Ohtake J, Homma S, Kawamura H, et al. Interleukin-6\/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Sci. 2017;108:1947\u201352.","journal-title":"Cancer Sci"},{"key":"75_CR16","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s10147-017-1161-7","volume":"22","author":"X Zhang","year":"2017","unstructured":"Zhang X, Zeng Y, Qu Q, Zhu J, Liu Z, Ning W, et al. PD-L1 induced by IFN-\u03b3 from tumor-associated macrophages via the JAK\/STAT3 and PI3K\/AKT signaling pathways promoted progression of lung cancer. Int J Clin Oncol. 2017;22:1026\u201333.","journal-title":"Int J Clin Oncol"},{"key":"75_CR17","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1073\/pnas.93.3.1320","volume":"93","author":"S Miyake","year":"1996","unstructured":"Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, et al. Efficient generation of recombinant adenoviruses using adenovirus DNAterminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci USA. 1996;93:1320\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"75_CR18","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/ijc.1474","volume":"94","author":"H Goto","year":"2001","unstructured":"Goto H, Osaki T, Kijima T, Nishino K, Kumagai T, Funakoshi T, et al. Gene therapy utilizing the Cre\/loxP system selectively suppresses tumor growth of disseminated carcinoembryonic antigen-producing cancer cells. Int J Cancer. 2001;94:414\u20139.","journal-title":"Int J Cancer"},{"key":"75_CR19","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1120>3.0.CO;2-1","volume":"91","author":"K Nishino","year":"2001","unstructured":"Nishino K, Osaki T, Kumagai T, Kijima T, Tachibana I, Goto H, et al. Adenovirus-mediated gene therapy specific for small cell lung cancer cells using a Myc-Max binding motif. Int J Cancer. 2001;91:851\u20136.","journal-title":"Int J Cancer"},{"key":"75_CR20","first-page":"4906","volume":"59","author":"T Kijima","year":"1999","unstructured":"Kijima T, Osaki T, Nishino K, Kumagai T, Funakoshi T, Goto H, et al. Application of the Cre recombinase\/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer. Cancer Res. 1999;59:4906\u201311.","journal-title":"Cancer Res"},{"key":"75_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/cgt.2017.21","volume":"24","author":"H Saito","year":"2017","unstructured":"Saito H, Kitagawa K, Yoneda T, Fukui Y, Fujsawa M, Bautista D, et al. Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro. Cancer Gene Ther. 2017;24:289\u201396.","journal-title":"Cancer Gene Ther"},{"key":"75_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.7883\/yoken1952.47.157","volume":"47","author":"Y Kanegae","year":"1994","unstructured":"Kanegae Y, Makimura M, Saito I. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol. 1994;47:157\u201366.","journal-title":"Jpn J Med Sci Biol"},{"key":"75_CR23","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/nprot.2006.238","volume":"1","author":"C Riccardi","year":"2006","unstructured":"Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 2006;1:1458\u201361.","journal-title":"Nat Protoc"},{"key":"75_CR24","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1200\/JCO.2010.31.8907","volume":"30","author":"P Sansone","year":"2012","unstructured":"Sansone P, Bromberg J. Targeting the interleukin-6\/Jak\/stat pathway in human malignancies. J Clin Oncol. 2012;30:1005\u201301014.","journal-title":"J Clin Oncol"},{"key":"75_CR25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0022-5347(01)62092-5","volume":"161","author":"HL Adler","year":"1999","unstructured":"Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol. 1999;161:182\u20137.","journal-title":"J Urol"},{"key":"75_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj20030407","volume":"374","author":"PC Heinrich","year":"2003","unstructured":"Heinrich PC, Behrmann I, Haan S, Hermanns HM, M\u00fcller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374:1\u201320.","journal-title":"Biochem J"},{"key":"75_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.eururo.2016.06.018","volume":"71","author":"N Don-Doncow","year":"2017","unstructured":"Don-Doncow N, Marginean F, Coleman I, Nelson PS, Ehrnstr\u00f6m R, Krzyzanowska A, et al. Expression of STAT3 in prostate cancer metastases. Eur Urol. 2017;71:313\u20136.","journal-title":"Eur Urol"},{"key":"75_CR28","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1158\/0008-5472.CAN-13-0874","volume":"73","author":"P Kroon","year":"2013","unstructured":"Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M, Bhasin D, Chettiar S, Li C, Li PK, Maitland NJ, Collins AT. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res. 2013;73:5288\u201398.","journal-title":"Cancer Res"},{"key":"75_CR29","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/cas.13493","volume":"109","author":"S Huang","year":"2018","unstructured":"Huang S, Liu Q, Liao Q, Wu Q, Sun B, Yang Z, et al. Interleukin-6\/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression. Cancer Sci. 2018;109:678\u201387.","journal-title":"Cancer Sci"},{"key":"75_CR30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/(SICI)1097-0045(19990215)38:3<199::AID-PROS4>3.0.CO;2-H","volume":"38","author":"TD Chung","year":"1999","unstructured":"Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate. 1999;38:199\u2013207.","journal-title":"Prostate"},{"key":"75_CR31","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/sj.onc.1206247","volume":"22","author":"J Clark","year":"2003","unstructured":"Clark J, Edwards S, Feber A, Flohr P, John M, Giddings I, et al. Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene. 2003;22:1247\u201352.","journal-title":"Oncogene"},{"key":"75_CR32","doi-asserted-by":"publisher","first-page":"26267","DOI":"10.1074\/jbc.271.42.26267","volume":"271","author":"ET Keller","year":"1996","unstructured":"Keller ET, Chang C, Ershler WB. Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J Biol Chem. 1996;271:26267\u201375.","journal-title":"J Biol Chem"},{"key":"75_CR33","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1590\/S1677-55382008000300013","volume":"34","author":"LA Asbagh","year":"2008","unstructured":"Asbagh LA, Uzunoglu S, Cal C. Zoledronic acid effects interleukin-6 expression in hormone-independent prostate cancer cell lines. Int Braz J Urol. 2008;34:355\u201363.","journal-title":"Int Braz J Urol"},{"key":"75_CR34","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.4161\/onci.21335","volume":"1","author":"L Zitvogel","year":"2012","unstructured":"Zitvogel L, Kroemer G. Targeting PD-1\/PD-L1 interactions for cancer immunotherapy. Oncoimmunology. 2012;1:1223\u20135.","journal-title":"Oncoimmunology"},{"key":"75_CR35","doi-asserted-by":"publisher","first-page":"pii: E2129","DOI":"10.3390\/ijms18102129","volume":"18","author":"A Beldi-Ferchiou","year":"2017","unstructured":"Beldi-Ferchiou A, Caillat-Zucman S. Control of NK cell activation by immune checkpoint molecules. Int J Mol Sci. 2017;18:pii: E2129.","journal-title":"Int J Mol Sci"},{"key":"75_CR36","doi-asserted-by":"publisher","first-page":"656340","DOI":"10.1155\/2012\/656340","volume":"2012","author":"EN Rozali","year":"2012","unstructured":"Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol. 2012;2012:656340.","journal-title":"Clin Dev Immunol"},{"key":"75_CR37","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-16-0224","volume":"22","author":"M Mandai","year":"2016","unstructured":"Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I. Dual faces of IFN\u03b3 in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin Cancer Res. 2016;22:2329\u201334.","journal-title":"Clin Cancer Res"},{"key":"75_CR38","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1093\/humrep\/deu172","volume":"29","author":"YJ Kang","year":"2014","unstructured":"Kang YJ, Jeung IC, Park A, Park YJ, Jung H, Kim TD, et al. An increased level of IL-6 suppresses NK cell activity in peritoneal fluid of patients with endometriosis via regulation of SHP-2 expression. Hum Reprod. 2014;29:2176\u201389.","journal-title":"Hum Reprod"},{"key":"75_CR39","doi-asserted-by":"crossref","unstructured":"Nakagawa S, Serada S, Kakubari R, Hiramatsu K, Sugase T, Matsuzaki S, et al. Intratumoral delivery of an adenoviral vector carrying the SOCS-1 gene enhances T cell-mediated anti-tumor immunity by suppressing PD-L1. Mol. Cancer Ther. 2018;17:1941\u201350.","DOI":"10.1158\/1535-7163.MCT-17-0822"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0075-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0075-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0075-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:10:10Z","timestamp":1684617010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-018-0075-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,4]]},"references-count":39,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["75"],"URL":"https:\/\/doi.org\/10.1038\/s41417-018-0075-5","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,4]]},"assertion":[{"value":"1 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}